Results 131 to 140 of about 6,032 (153)

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction

Circulation, 2020
Giuseppe Gargiulo, Giovanni Esposito, Michael Nagler   +2 more
exaly  

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

Lancet, The, 2008
Jurrien Ten Berg, Jan Paul Ottervanger, Christian W Hamm   +2 more
exaly  

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban

Lancet, The, 1999
Christian W Hamm
exaly  

Therapeutic efficiency of tirofiban in acute coronary syndromes

Lancet, The, 2000
Christian W Hamm
exaly   +2 more sources

Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke

Stroke, 2020
Andrew Bivard, Mark W Parsons, Longting Lin   +2 more
exaly  

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

Lancet, The, 2002
Eric J Topol
exaly  

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization

New England Journal of Medicine, 2001
Eric J Topol
exaly  

Tirofiban

Reactions Weekly, 2011
openaire   +2 more sources

Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban

New England Journal of Medicine, 2001
Christopher P Cannon, William S Weintraub, Franz-Josef Neumann   +2 more
exaly  

Tirofiban

Inpharma Weekly, 1998
openaire   +1 more source